Home・Список акций・Charles River Laboratories International Inc

Charles River Laboratories International Inc

Закрыт

СекторЗдравоохранение

279.83 0.04

Купить Продать

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

276.14

Макс.

281.83

Ключевые показатели
By Trading Economics
Доход	14M -760K
Продажи	8.2M 1B
Прибыль на акцию	3.02
Рентабельность продаж	-0.076
Сотрудники	18,300
EBITDA	87M 151M

Рекомендации
By TipRanks
Рекомендации	Активная покупка
Прогноз на 12 месяцев	+1.2% upside

Дивиденды
By Acuity
Следующий отчет о доходах	4 нояб. 2026 г.

Рыночная статистика
By TradingEconomics
Рыночная капитализация	2B 13B
Предыдущая цена открытия	279.79
Предыдущая цена закрытия	279.83

Новостные настроения

By Acuity

50%

171 / 340 Рейтинг в Healthcare

Charles River Laboratories International Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

13 авг. 2026 г., 19:52 UTC

Correlated Moves

Charles River Laboratories shares are lower today amid rising jobless claims and volatility, reflecting a decline since Wednesday's close.

12 авг. 2026 г., 20:51 UTC

Charles River Laboratories is higher in after-market trading, reflecting positive momentum despite no specific news. Broader market dynamics appear to support this resilience.

11 авг. 2026 г., 19:56 UTC

Charles River Laboratories International Inc. shares are trading higher today, maintaining a position above the 20-day moving average amid routine price movements.

10 авг. 2026 г., 19:16 UTC

News

Charles River Laboratories shares rise as TD Cowen and Mizuho raise price targets to $300 and $264, respectively. The stock shows notable strength since Friday.

7 авг. 2026 г., 19:51 UTC

News

Morgan Stanley raised its price target on Charles River Laboratories to $300, maintaining an Overweight rating as shares move higher since Thursday's close.

6 авг. 2026 г., 22:51 UTC

Shares of Charles River Laboratories International Inc. are lower in after-market trading, continuing a decline from Thursday's close despite being above its 20-day moving average.

5 авг. 2026 г., 23:56 UTC

Charles River Laboratories is higher in after-market hours, recovering from session lows. Broader market sentiment is affected by a disappointing ADP employment report.

4 авг. 2026 г., 19:16 UTC

Correlated Moves

Charles River Laboratories is rising amid positive momentum in the small-cap market, supported by a drop in crude oil prices that eases inflation concerns.

3 авг. 2026 г., 22:06 UTC

Charles River Laboratories shares are slightly higher in after-hours trading, supported by stronger-than-expected manufacturing data showing a rise in the PMI for July.

31 июл. 2026 г., 19:46 UTC

Correlated Moves

Charles River Laboratories reported first-quarter revenue of $1.02 billion and adjusted EPS of $2.06, but shares are lower amid broader market declines.

30 июл. 2026 г., 23:01 UTC

Shares of Charles River Laboratories are higher in after-market trading, reaching a peak above Thursday's close and remaining strong relative to recent trends.

29 июл. 2026 г., 19:18 UTC

Correlated Moves

Charles River Laboratories is lower today amid broader market declines and investor caution ahead of the Federal Reserve's monetary policy announcement.

28 июл. 2026 г., 18:02 UTC

Charles River Laboratories is trading higher today, continuing a strong rally since Monday. The stock remains above its 20-day moving average.

27 июл. 2026 г., 17:36 UTC

News

Correlated Moves

Charles River Laboratories is trading lower today, reflecting a decline since Friday. The company announced a collaboration with Arovella Therapeutics for GMP sequencing services.

23 июл. 2026 г., 00:01 UTC

Charles River Laboratories is higher in after-hours trading, maintaining a cumulative gain since Wednesday amid no specific news to explain the movement.

22 июл. 2026 г., 22:01 UTC

Charles River Laboratories shares are higher in after-hours trading, reflecting a notable increase since Wednesday's close and positioning above the 20-day moving average.

21 июл. 2026 г., 21:01 UTC

Charles River Laboratories shares moved lower in after-market trading, continuing a steady decline since Tuesday's close amid broader market concerns.

20 июл. 2026 г., 21:01 UTC

Shares of Charles River Laboratories International Inc are lower in after-market trading, continuing a trend of declines with no specific news to explain the movement.

Сравнение c конкурентами

Изменение цены

Charles River Laboratories International Inc Прогноз

Целевая цена

By TipRanks

1.2% рост

Прогноз на 12 месяцев

Средняя 284.64 USD 1.2%

Максимум 310 USD

Минимум 219 USD

Основано на мнении 13 аналитиков Wall Street, спрогнозировавших целевые цены для Charles River Laboratories International Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Активная покупка

13 ratings

Покупка

Удержание

Продажа

Основано на мнении 13 аналитиков, присваивавших рейтинги акциям Charles River Laboratories International Inc – Данные за последние 3 месяца.

Настроения

By Acuity

171 / 340Рейтинг в Здравоохранение

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

О компании Charles River Laboratories International Inc

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.